Age-relatedMacularDegeneration (ARMD) Drugs Market - Global Outlook and Forecast 2024-2031

Report ID: 1366276 | Published Date: Sep 2024 | No. of Page: 63 | Base Year: 2023 | Rating: 4.8 | Webstory: Check our Web story

This report contains market size and forecasts of Age-relatedMacularDegeneration (ARMD) Drugs in Global, including the following market information:
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Age-relatedMacularDegeneration (ARMD) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Anti VEGF Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Age-relatedMacularDegeneration (ARMD) Drugs include Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, Kanghong Pharmaceuticals, Novartis, Eli Lilly and Company, TRACON Pharmaceuticals and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Age-relatedMacularDegeneration (ARMD) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Type, 2021 (%)
Anti VEGF Drugs
Photosensitive Drugs
Others
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Application, 2021 (%)
Exudative ARMD
Atrophy ARMD
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD

Frequently Asked Questions
Age-relatedMacularDegeneration Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Age-relatedMacularDegeneration Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Age-relatedMacularDegeneration Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports